244 related articles for article (PubMed ID: 22508869)
1. Risk of serious adverse events associated with biologic and nonbiologic psoriasis systemic therapy: patients ineligible vs eligible for randomized controlled trials.
Garcia-Doval I; Carretero G; Vanaclocha F; Ferrandiz C; Daudén E; Sánchez-Carazo JL; Alsina M; Herrera-Ceballos E; Gómez-García FJ; Ferrán M; López-Estebaranz JL; Hernanz JM; Belinchón-Romero I; Vilar-Alejo J; Rivera R; Carrascosa JM; Carazo C
Arch Dermatol; 2012 Apr; 148(4):463-70. PubMed ID: 22508869
[TBL] [Abstract][Full Text] [Related]
2. Risk of adverse events in psoriasis patients receiving classic systemic drugs and biologics in a 5-year observational study of clinical practice: 2008-2013 results of the Biobadaderm registry.
Carretero G; Ferrandiz C; Dauden E; Vanaclocha Sebastián F; Gómez-García FJ; Herrera-Ceballos E; De la Cueva-Dobao P; Belinchón I; Sánchez-Carazo JL; Alsina-Gibert M; López-Estebaranz JL; Ferrán M; Torrado R; Carrascosa JM; Carazo C; Rivera R; Jiménez-Puya R; García-Doval I;
J Eur Acad Dermatol Venereol; 2015 Jan; 29(1):156-63. PubMed ID: 24684267
[TBL] [Abstract][Full Text] [Related]
3. Safety of classic and biologic systemic therapies for the treatment of psoriasis in elderly: an observational study from national BIOBADADERM registry.
Medina C; Carretero G; Ferrandiz C; Dauden E; Vanaclocha F; Gómez-García FJ; Herrera-Ceballos E; De la Cueva-Dobao P; Belinchón I; Sánchez-Carazo JL; Alsina M; López-Estebaranz JL; Ferrán M; Carrascosa JM; Torrado R; Argila D; Rivera R; Jiménez-Puya R; García-Doval I;
J Eur Acad Dermatol Venereol; 2015 May; 29(5):858-64. PubMed ID: 25185962
[TBL] [Abstract][Full Text] [Related]
4. Safety of treatment with biologics for psoriasis in daily practice: 5-year data.
van Lümig PP; Driessen RJ; Berends MA; Boezeman JB; van de Kerkhof PC; de Jong EM
J Eur Acad Dermatol Venereol; 2012 Mar; 26(3):283-91. PubMed ID: 21435026
[TBL] [Abstract][Full Text] [Related]
5. Risk of Serious Infection With Biologic and Systemic Treatment of Psoriasis: Results From the Psoriasis Longitudinal Assessment and Registry (PSOLAR).
Kalb RE; Fiorentino DF; Lebwohl MG; Toole J; Poulin Y; Cohen AD; Goyal K; Fakharzadeh S; Calabro S; Chevrier M; Langholff W; You Y; Leonardi CL
JAMA Dermatol; 2015 Sep; 151(9):961-9. PubMed ID: 25970800
[TBL] [Abstract][Full Text] [Related]
6. Adverse drug events in infliximab-treated patients compared with the general and psoriasis populations.
Menter A; Reich K; Gottlieb AB; Bala M; Li S; Hsu MC; Guzzo C; Diels J; Gelfand JM
J Drugs Dermatol; 2008 Dec; 7(12):1137-46. PubMed ID: 19137767
[TBL] [Abstract][Full Text] [Related]
7. Safety observations in 12095 patients with psoriasis enrolled in an international registry (PSOLAR): experience with infliximab and other systemic and biologic therapies.
Gottlieb AB; Kalb RE; Langley RG; Krueger GG; de Jong EM; Guenther L; Goyal K; Fakharzadeh S; Chevrier M; Calabro S; Langholff W; Menter A
J Drugs Dermatol; 2014 Dec; 13(12):1441-8. PubMed ID: 25607786
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of psoralen plus ultraviolet A therapy vs. biologics in moderate to severe chronic plaque psoriasis: retrospective data analysis of a patient registry.
Inzinger M; Heschl B; Weger W; Hofer A; Legat FJ; Gruber-Wackernagel A; Tilz H; Salmhofer W; Quehenberger F; Wolf P
Br J Dermatol; 2011 Sep; 165(3):640-5. PubMed ID: 21564068
[TBL] [Abstract][Full Text] [Related]
9. Malignancy rates in a large cohort of patients with systemically treated psoriasis in a managed care population.
Asgari MM; Ray GT; Geier JL; Quesenberry CP
J Am Acad Dermatol; 2017 Apr; 76(4):632-638. PubMed ID: 28162854
[TBL] [Abstract][Full Text] [Related]
10. Long-term safety of biologics in the treatment of moderate-to-severe plaque psoriasis: review of current data.
Rustin MH
Br J Dermatol; 2012 Nov; 167 Suppl 3():3-11. PubMed ID: 23082810
[TBL] [Abstract][Full Text] [Related]
11. Patients enrolled in coronary intervention trials are not representative of patients in clinical practice: results from the Euro Heart Survey on Coronary Revascularization.
Hordijk-Trion M; Lenzen M; Wijns W; de Jaegere P; Simoons ML; Scholte op Reimer WJ; Bertrand ME; Mercado N; Boersma E;
Eur Heart J; 2006 Mar; 27(6):671-8. PubMed ID: 16423872
[TBL] [Abstract][Full Text] [Related]
12. A standardization approach to compare treatment safety and effectiveness outcomes between clinical trials and real-world populations in psoriasis.
Yiu ZZN; Mason KJ; Barker JNWN; Hampton PJ; McElhone K; Smith CH; Warren RB; Griffiths CEM; Lunt M; Burden AD;
Br J Dermatol; 2019 Dec; 181(6):1265-1271. PubMed ID: 30822358
[TBL] [Abstract][Full Text] [Related]
13. The effect of systemic psoriasis therapies on the incidence of myocardial infarction: a cohort study.
Abuabara K; Lee H; Kimball AB
Br J Dermatol; 2011 Nov; 165(5):1066-73. PubMed ID: 21777216
[TBL] [Abstract][Full Text] [Related]
14. Serious infections among a large cohort of subjects with systemically treated psoriasis.
Dobry AS; Quesenberry CP; Ray GT; Geier JL; Asgari MM
J Am Acad Dermatol; 2017 Nov; 77(5):838-844. PubMed ID: 28917384
[TBL] [Abstract][Full Text] [Related]
15. The risk of cancer in patients with psoriasis: a population-based cohort study in Taiwan.
Chen YJ; Wu CY; Chen TJ; Shen JL; Chu SY; Wang CB; Chang YT
J Am Acad Dermatol; 2011 Jul; 65(1):84-91. PubMed ID: 21458106
[TBL] [Abstract][Full Text] [Related]
16. Use of biologic agents in pediatric psoriasis.
Marji JS; Marcus R; Moennich J; Mackay-Wiggan J
J Drugs Dermatol; 2010 Aug; 9(8):975-86. PubMed ID: 20684148
[TBL] [Abstract][Full Text] [Related]
17. Association between systemic antipsoriatic drugs and cardiovascular risk in patients with psoriasis with or without psoriatic arthritis: a nationwide cohort study.
Chen YJ; Chang YT; Shen JL; Chen TT; Wang CB; Chen CM; Wu CY
Arthritis Rheum; 2012 Jun; 64(6):1879-87. PubMed ID: 22161801
[TBL] [Abstract][Full Text] [Related]
18. External validity of clinical trials in acute myocardial infarction.
Steg PG; López-Sendón J; Lopez de Sa E; Goodman SG; Gore JM; Anderson FA; Himbert D; Allegrone J; Van de Werf F;
Arch Intern Med; 2007 Jan; 167(1):68-73. PubMed ID: 17210880
[TBL] [Abstract][Full Text] [Related]
19. Differential outcomes after sirolimus-eluting stent implantation: comparing on-label versus off-label patients in the 'real world'.
Jeremias A; Ruisi CP; Kirtane AJ; Lee T; Sylvia B; Pinto DS; Ho KK; Cutlip DE; Carrozza JP; Cohen DJ
Coron Artery Dis; 2008 Mar; 19(2):111-5. PubMed ID: 18300748
[TBL] [Abstract][Full Text] [Related]
20. The risk of squamous cell and basal cell cancer associated with psoralen and ultraviolet A therapy: a 30-year prospective study.
Stern RS;
J Am Acad Dermatol; 2012 Apr; 66(4):553-62. PubMed ID: 22264671
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]